AgingResearch.NewsJoin free

Endeavor BioMedicines

CompanyUnited States

Endeavor BioMedicines develops one asset, in phase 2 (taladegib in idiopathic pulmonary fibrosis). Mostly small molecule acting on SMO; based in the United States.

1
Asset
Furthest stage
Phase 2
0
Trials
0
Signals

Pipeline

1

  • taladegib

    Inhibitor of the Hedgehog signaling pathway.

    Phase 2, Small molecule, SMO, idiopathic pulmonary fibrosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Signals1
  • Similar companies6

Intelligence